Yes — this is a reasonable next move, with one important reframing:

> The cluster-29 basin experiment should be treated as a **method-development stress test**, not the final scientific target.
> The final objective is **cohort-level enrichment of empirically under-covered regions across the full real-note manifold**, subject to clinical validity, source faithfulness, privacy, and diversity constraints.

That is consistent with the project’s research plan. The plan defines the real target as the **full filtered 1024-dimensional embedding manifold**, identifies sparse and subgroup-skewed regions across the cohort, and treats exact single-cluster occupancy as a diagnostic rather than the ultimate endpoint. ([GitHub][1])

I’ll keep this as the standing research objective going forward.

## What stage are we actually at?

You have completed a successful **local proof of feasibility**:

```text
A sparse local basin was identified
→ target-basin anchors were selected
→ multiple ELM candidates were generated
→ final generated text was re-embedded
→ strict geometric and surface-quality gates retained 106 notes
```

The 8192-token rerun demonstrated that closed-loop selection can generate a nontrivial set of complete notes in or near an under-covered real-data region.

But it has not yet demonstrated three things required for the full project claim:

1. that accepted notes are clinically better than fair controls;
2. that the enrichment method generalizes beyond one chosen basin;
3. that applying it improves coverage across the broader cohort rather than merely producing more notes near clusters 9, 17, 29, and 45.

So the next stage should be **validation plus generalization design**, not raw scale-up.

# Recommended revised plan

## Track A — Validate the current local-basin pilot

Your proposed self-check is correct.

### A1. Freeze the 8192-token run

Preserve:

* the 106 accepted notes;
* all 2,048 candidates;
* input anchors;
* re-embedded outputs;
* target and source scores;
* code commit;
* run configuration;
* privacy outputs;
* accepted/rejected manifests.

This becomes the fixed Phase 2 pilot dataset.

### A2. Generate a fair vanilla comparator

The comparator must use:

```text
same anchor/source rows
same ELM checkpoint
same default prompt
same max_new_tokens = 8192
same temperature/top-p/top-k
same repetition penalty
same number of independent source rows
no target-basin rejection or reranking
```

The previous 2048-token vanilla notes should remain in the report as the historical Phase 1 baseline, but they should not be the primary comparator for the new 8192-token method.

The proper question is:

> Given equivalent generation conditions, does closed-loop generate–embed–filter selection improve coverage and clinical quality over ordinary ELM sampling?

### A3. Complete the blinded clinical review

The review should include:

* accepted closed-loop candidates;
* fair 8192-token vanilla notes;
* within-anchor candidates that passed most gates but were not selected;
* a limited set of obvious collapse failures as positive controls for the review rubric.

A validated clinical-summary instrument such as PDSQI-9 offers useful domains—including accuracy, thoroughness, usefulness, organization, comprehensibility, succinctness, and synthesis—but your task also requires additional synthetic-data-specific domains: internal temporal consistency, diagnosis–procedure agreement, medication plausibility, source faithfulness, privacy, and narrative unity. ([Nature][2])

### A4. Add source-paired factual review

The current blinded review asks whether a note is internally plausible. It cannot tell whether the note is faithful to its conditioning source.

For a subset, show reviewers:

```text
real source discharge note
+
synthetic note
```

Then score:

* principal diagnosis retention;
* major procedure retention;
* major complication retention;
* medication-change retention;
* discharge disposition agreement;
* demographic agreement;
* unsupported major claims;
* clinically important omissions.

This is particularly important because recent large-scale work on synthetic clinical notes reports that errors commonly involve temporal confusion, measurement errors, fabricated claims, and misinterpretation of clinical context—very similar to the issues found in your accepted notes. ([arXiv][3])

### A5. Fix the target-gate accounting

Correct the aliasing so each candidate independently records:

```text
nearest_cluster_in_target
true_basin_membership
target_centroid_distance_pass
local_density/support pass
final_hybrid_target_gate_pass
```

Do not collapse these into one field.

The accepted notes should then be classified by **how** they entered the accepted set:

* exact target-cluster membership;
* broader predefined basin membership;
* centroid-proximity only;
* multiple target criteria.

That makes the basin-enrichment claim auditable.

# Track B — Generalize from one basin to the full cohort

This should be designed now, but executed only after Track A confirms that the notes are sufficiently valid.

## B1. Define cohort-level under-coverage

Do not define the final target as cluster 29 or any one CAV axis.

For every real cohort note or local neighborhood, compute an under-coverage score based on quantities such as:

```text
real-data local density
synthetic-data local density
distance from each real note to nearest synthetic note
real-to-synthetic neighborhood coverage
subgroup representation deficit
clinical-cohort importance
```

Conceptually:

```text
undercoverage(x)
=
high real support
+ high real-to-synthetic distance
+ low synthetic local density
+ optional subgroup/clinical importance
```

This identifies sparse **coverage gaps throughout the manifold**, including gaps that do not align cleanly with K-means boundaries.

The research plan already says that coverage claims should come from the full normalized 1024-dimensional space and that PCA/UMAP/t-SNE should only be used for visualization. ([GitHub][1])

## B2. Convert the manifold into multiple enrichment regions

Instead of selecting one cluster, identify a set of candidate regions:

```text
Region 1: severe under-coverage, strong real support
Region 2: moderate under-coverage, subgroup-skewed
Region 3: clinically distinct but underrepresented
...
```

These can be based on:

* local connected components;
* k-nearest-neighbor neighborhoods;
* density basins;
* collections of adjacent clusters;
* clinically coherent metadata-linked regions.

The final region definition should require both:

1. geometric evidence that it is under-covered;
2. clinical evidence that the region is meaningful or coherent.

## B3. Allocate generation adaptively across the cohort

Do not generate the same number of candidates everywhere.

Allocate candidate budgets based on deficit:

```text
more candidates
→ regions with greater real–synthetic coverage deficit

fewer candidates
→ already well-covered regions
```

A simple policy might be:

```text
candidate budget for region r
∝
region size × undercoverage severity
```

Then use real anchors from each target region and the same closed-loop output-space method.

## B4. Use cohort-level success metrics

The primary Phase 2 endpoint should not be:

```text
How many notes landed in cluster 29?
```

It should be:

> Does the enriched synthetic corpus improve coverage of the under-covered real cohort relative to matched vanilla generation, without unacceptable loss of clinical validity, source faithfulness, privacy, or diversity?

Primary metrics could include:

* real-to-synthetic nearest-neighbor distance across the full cohort;
* percentage of under-covered real notes brought below a prespecified coverage-distance threshold;
* change in local synthetic density in targeted regions;
* low-density-region coverage;
* subgroup-stratified coverage;
* number of distinct real anchors represented;
* accepted-note clinical pass rate;
* full-corpus privacy-risk measures.

Single-cluster occupancy remains useful as a diagnostic for understanding decoder behavior, but not as the final endpoint.

## B5. Compare against meaningful baselines

The cohort-level enrichment method should beat:

1. matched vanilla generation;
2. extra vanilla sampling with the same total compute budget;
3. random selection of additional synthetic notes;
4. ideally, density-weighted anchor sampling without closed-loop filtering.

This is essential. Otherwise, improved coverage may simply result from generating more candidates rather than from the enrichment method itself.

The existing research plan explicitly requires enrichment conditions to beat matched vanilla and a random/control perturbation before scale-up. ([GitHub][1])

# Where clinical validity fits

Clinical validity should not replace the enrichment objective, but it must become a **constraint on enrichment**.

The project objective can be written as:

```text
maximize cohort-level coverage improvement

subject to:
- acceptable clinical validity
- acceptable source faithfulness
- privacy/memorization limits
- diversity requirements
- leakage-aware evaluation
```

This matters because statistical or embedding similarity alone can overstate synthetic-data quality. Current reviews recommend evaluating synthetic health data across multiple complementary dimensions, especially utility, fidelity, privacy, and domain validity rather than relying on one similarity metric. ([PMC][4])

# When should a clinical reranker or editor be added?

Not immediately.

First complete the fair comparison.

### If accepted closed-loop notes are clinically better than fair vanilla

Then preserve the current generator and add a lightweight clinical reranker to improve yield:

```text
generate candidates
→ embedding-region gate
→ source-faithfulness gate
→ clinical-consistency reranker
→ privacy/diversity gate
```

### If accepted notes are not clinically better than fair vanilla

Then the current filter improves coverage but not clinical validity. In that case, a **source-grounded repair stage** becomes justified:

```text
ELM draft
→ extract source facts
→ detect unsupported or contradictory claims
→ repair note using source facts
→ re-embed repaired note
→ require target-region retention
→ rerun quality/privacy gates
```

The repaired note must be re-embedded because editing may move it back out of the under-covered region.

### If both generation and repair remain poor

Then the project may need section-wise or structured-fact-conditioned decoding rather than whole-note free generation.

# Immediate ordered next steps

1. Freeze the successful 106-note pilot.
2. Complete and analyze the blinded clinical review.
3. Generate the fair matched 8192-token vanilla baseline.
4. Perform source-paired faithfulness review.
5. Correct target-gate route accounting.
6. Determine whether accepted notes are clinically better than fair controls.
7. Build a cohort-wide under-coverage score and identify multiple enrichment regions.
8. Run a small multi-region generalization pilot.
9. Only then scale candidate counts or total cohort coverage.

## The scientific framing to preserve

> We are developing a closed-loop ELM generation framework to enrich empirically under-covered regions of the full clinical-note embedding manifold. Local clusters and basins are used as controlled development targets, but the final goal is cohort-level coverage improvement. Enrichment is considered successful only when it improves real-manifold coverage relative to equal-compute vanilla baselines while retaining clinically valid, source-faithful, diverse, privacy-screened synthetic notes.

So yes: **your self-check plan is correct**. The refinement is to make explicit that validating the cluster-29 basin pilot is the bridge to a multi-region, full-cohort enrichment experiment—not the final project destination.

[1]: https://raw.githubusercontent.com/0oJimmyo0/synth-notes/main/research_plan.tex "raw.githubusercontent.com"
[2]: https://www.nature.com/articles/s41746-025-02005-2?utm_source=chatgpt.com "Evaluating clinical AI summaries with large language ..."
[3]: https://arxiv.org/abs/2605.17775?utm_source=chatgpt.com "Systematic Evaluation of the Quality of Synthetic Clinical Notes Rephrased by LLMs at Million-Note Scale"
[4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11772694/?utm_source=chatgpt.com "A scoping review of privacy and utility metrics in medical ..."
